PERBANDINGAN WARFARIN DAN DIRECT ORAL ANTICOAGULANTS (DOACS) PADA OPTIMISASI MANAJEMEN RISIKO TROMBOEMBOLI PADA FIBRILASI ATRIUM
DOI:
https://doi.org/10.31004/cdj.v6i1.42551Keywords:
Fibrilasi Atrium, Warfarin, DOACs, Rivaroxaban, Stroke, TromboemboliAbstract
Fibrilasi Atrium (FA) merupakan gangguan irama jantung yang meningkatkan risiko tromboemboli, termasuk stroke. Penelitian ini membandingkan efektivitas, keamanan, dan farmakoekonomi antara Warfarin dan Direct Oral Anticoagulants (DOACs), khususnya Rivaroxaban, dalam pengelolaan risiko tromboemboli pada pasien FA. Berdasarkan analisis dari tiga jurnal utama, DOACs lebih efektif dalam mengurangi stroke dan embolus sistemik serta perdarahan intrakranial dibandingkan Warfarin. Meskipun DOACs lebih mahal, mereka lebih hemat biaya dalam jangka panjang karena tidak memerlukan pemantauan rutin INR dan mengurangi biaya terkait komplikasi serius. Rivaroxaban menunjukkan profil keamanan yang lebih baik, terutama pada pasien dengan obesitas, penyakit ginjal kronis, dan polifarmasi, serta memiliki risiko perdarahan mayor yang lebih rendah. Meskipun ada peningkatan risiko perdarahan gastrointestinal, keuntungan dalam kemudahan penggunaan menjadikan DOACs, terutama Rivaroxaban, pilihan yang lebih baik dalam pengelolaan fibrilasi atrium.References
Sagris, M., Vardas, E. P., Theofilis, P., Antonopoulos, A. S., Oikonomou, E., & Tousoulis, D. (2022). Atrial fibrillation: Pathogenesis, predisposing factors, and genetics. International Journal of Molecular Sciences, 23(1). https://doi.org/10.3390/ijms23010006
Burdett, P., & Lip, G. Y. H. (2022). Atrial fibrillation in the UK: Predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. European Heart Journal - Quality of Care and Clinical Outcomes, 8(2), 187–194. https://doi.org/10.1093/ehjqcco/qcaa093
Yogi, et all. (2024). Hubungan Antara Usia Dengan Kejadian Gagal Jantung Pada Pasien Atrial Fibrilasi Di Rumah Sakit Jantung Hasna Medikn,A Cirebon. Tunas Med, 10(1). https://www.ejournalugj.com/index.php/tumed/article/view/9330/4257
Elsheikh, S., Hill, A., Irving, G., Lip, G. Y. H., & Abdul-Rahim, A. H. (2024). Atrial fibrillation and stroke: State-of-the-art and future directions. Current Problems in Cardiology, 49(1), 102181. https://doi.org/10.1016/j.cpcardiol.2023.102181
Elsheikh, S., Hill, A., Irving, G., Lip, G. Y. H., & Abdul-Rahim, A. H. (2024). Atrial fibrillation and stroke: State-of-the-art and future directions. Current Problems in Cardiology, 49(1), 102181. https://doi.org/10.1016/j.cpcardiol.2023.102181
Tamara, F. D. (2023). Perbandingan Efektivitas Rivaroxaban Dan Warfarin Dalam Mengatasi Kejadian Emboli Pada Pasien Dengan Atrial Fibrilasi. Jurnal Ners, 7(1), 731–737. https://doi.org/10.31004/jn.v7i1.14127
Lizal, R., & Suranadi, I. W. (2021). Laporan Kasus : Penanganan Fibrilasi Atrium Perioperatif. Medicina, 52(3), 140–142. https://doi.org/10.15562/medicina.v52i3.1086
Carlin, S., Cuker, A., Gatt, A., Gendron, N., Hernández-Gea, V., Meijer, K., Siegal, D. M., Stanworth, S., Lisman, T., & Roberts, L. N. (2024). Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 22(9), 2653–2669. https://doi.org/10.1016/j.jtha.2024.05.023
Mende, J., Rahmawati, F., & Puspitasari, I. (2022). Keamanan Penggunaan Antiglukolan pada Pasien Rawat Inap Stroke Iskemik dengan Atrial Fibrilasi. Jurnal Manajemen Dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice), 12(3), 176. https://doi.org/10.22146/jmpf.74893
Lee, T. T. L., Chan, S. C. L., Chou, O. H. I., Lee, S., Chan, J. S. K., Liu, T., Chang, C., Wong, W. T., Lip, G. Y. H., Cheung, B. M. Y., Wai, A. K. C., & Tse, G. (2024). Initiation of warfarin is associated with decreased mortality in patients with infective endocarditis: A population-based cohort study. Thrombosis Research, 233(July 2023), 1–9. https://doi.org/10.1016/j.thromres.2023.11.009
Raymond, J., Imbert, L., Cousin, T., Duflot, T., Varin, R., Wils, J., & Lamoureux, F. (2021). Pharmacogenetics of direct oral anticoagulants: A systematic review. Journal of Personalized Medicine, 11(1), 1–11. https://doi.org/10.3390/jpm11010037
Sagina, V. A., & Sukmadryani, Y. (2024). Analisis Efektivitas Biaya Penggunaan Obat Antikoagulan Di Indonesia : Kajian Artikel. Pharmacia Jurnal Farmasi
Carnicelli, A. P., Hong, H., Connolly, S. J., Eikelboom, J., Giugliano, R. P., Morrow, D. A., Patel, M. R., Wallentin, L., Alexander, J. H., Bahit, M. C., Benz, A. P., Bohula, E. A., Chao, T., Dyal, L., Ezekowitz, M., Fox, K. A. A., Gencer, B., Halperin, J. L., Hijazi, Z., … Fibrillation, A. (2022). Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex. 145(4), 242–255. https://doi.org/10.1161/CIRCULATIONAHA.121.056355.Corresponding
Kumar, V., & Ilkhanoff, L. (2024). Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors. Frontiers in Cardiovascular Medicine, 11(February), 1–6. https://doi.org/10.3389/fcvm.2024.1352734
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Syifa Salsabila Aulia Putri, St. Harlyanti Nur, Ilsyah Annastasya Ismail
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
